Although the above KDM inhibitors are not KDM3B-specific, these results provide insight into the possibility that pharmacological targeting of KDM3B in chemoresistant NSCLC cells could be a novel therapeutic strategy for lung cancer therapy and chemoresistant tumors. Here, KDM3B is linked to lung carcinoma.